Last Update Time:
05-Feb-2025 09:27:15
ISIN:
INE089A01031
Sector:
Healthcare
Symbol:
DRREDDY
Dr. Reddy's Laboratories Limited
₹1,227.00
₹7.05
(0.58%)
▲
Prev. Close
₹1,219.95
Open
₹1,227.00
Close
₹0.00
Range
₹1,165.65 - ₹1,288.35
High
₹1,229.95
Low
₹1,215.85
Ind. Close
₹0.00
VWAP
₹1,221.68
The current stock price of Dr. Reddy's Laboratories Limited is ₹1,227.00, with a target price range between ₹1,165.65 and ₹1,288.35. The stock has experienced a price change of ₹7.05 (0.58%), reflecting recent market volatility.
Today's opening price was ₹1,227.00, while the previous close stood at ₹1,219.95. The intraday high reached ₹1,229.95, and the low touched ₹1,215.85. The volume-weighted average price (VWAP) is currently ₹1,221.68, indicating the stock's average traded price.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Dr. Reddy's Laboratories Limited Price Chart
Dr. Reddy's Laboratories Limited Pre Open Market Overview: 05-Feb-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1227
- Previous Close Price: 1219.95
- Change: 7.05%
- Total Traded Volume: 1,859
- Total Buy Quantity: 7,143
- Total Sell Quantity: 14,122
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,222.00 | 25.00 | 0.00 |
| 1,223.05 | 2.00 | 0.00 |
| 1,223.95 | 10.00 | 0.00 |
| 1,225.05 | 2.00 | 0.00 |
| 1,227.00 | 389.00 | 0.00 |
| 1,230.00 | 0.00 | 52.00 |
| 1,231.90 | 0.00 | 70.00 |
| 1,232.00 | 0.00 | 10.00 |
| 1,233.00 | 0.00 | 66.00 |
| 1,235.00 | 0.00 | 42.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 1,226.95 | 5 | 1,227.00 | 1,182 |
| 1,226.90 | 92 | 1,227.05 | 37 |
| 1,226.70 | 2 | 1,227.10 | 2 |
| 1,226.60 | 68 | 1,227.20 | 1 |
| 1,226.50 | 79 | 1,227.25 | 21 |
Total Buy Quantity: 116,678
Total Sell Quantity: 97,933
Shareholding Patterns (in %) of Dr. Reddy's Laboratories Limited
| Category | 31-Dec-2023 | 31-Mar-2024 | 30-Jun-2024 | 30-Sep-2024 | 31-Dec-2024 |
|---|---|---|---|---|---|
| Promoter & Promoter Group | 26.65 | 26.65 | 26.65 | 26.64 | 26.64 |
| Public | 73.17 | 73.17 | 73.18 | 73.20 | 73.20 |
| Shares held by Employee Trusts | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 |
| Total | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
Key Trade Statistics of Dr. Reddy's Laboratories Limited
The trade information for Dr. Reddy's Laboratories Limited includes a total traded volume of 2.05 lakh shares, and a traded value of ₹25.00 crore.
The market cap is ₹102,383.82 crore, with a free float market cap of ₹74,635.61 crore. The deliverable quantity is 1,440,203.00 shares, reflecting 64.3% of total trades.
Key risk indicators include security VaR at 8.16% and an applicable margin rate of 12.5%.
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 2.05 |
| Traded Value (₹ Cr.) | 25.00 |
| Total Market Cap (₹ Cr.) | 102,383.82 |
| Free Float Market Cap (₹ Cr.) | 74,635.61 |
| Impact cost | 0.02 |
| Quantity Traded | 2,239,920.00 |
| Deliverable Quantity | 1,440,203.00 |
| % of Quantity to Traded | 64.3 |
| Security VaR | 8.16 |
| Index VaR | N/A |
| VaR Margin | 9 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 12.5 |
| Face Value | 1 |
Key Price Statistics of Dr. Reddy's Laboratories Limited
The 52-week high for Dr. Reddy's Laboratories Limited was ₹1,421.49, recorded on 21-Aug-2024. On the other hand, the 52-week low stands at ₹1,120.00, with the lowest value recorded on 04-Jun-2024.
The upper band for trading is ₹N/A, and the lower band is ₹N/A. The price band is No Band%.
The stock's daily volatility stands at 1.31, while the annualized volatility is 25.03. The tick size for trading is ₹N/A.
| Price Information | Details |
|---|---|
| 52 Week High (21-Aug-2024) | 1,421.49 |
| 52 Week Low (04-Jun-2024) | 1,120.00 |
| Upper Band | 1,341.90 |
| Lower Band | 1,097.95 |
| Price Band (%) | No Band |
| Daily Volatility | 1.31 |
| Annualised Volatility | 25.03 |
| Tick Size | 0.05 |
Key Securities Statistics of Dr. Reddy's Laboratories Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 30-May-2003 |
| Adjusted P/E | 18.75 |
| Symbol P/E | 18.75 |
| Index | NIFTY 50 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Dr. Reddy's Laboratories Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Dr. Reddy's Laboratories Limited
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 04-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 04-Feb-2025 |
| Action(s) taken or orders passed | 03-Feb-2025 |
| Action(s) taken or orders passed | 02-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 29-Jan-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 29-Jan-2025 |
| Updates | 24-Jan-2025 |
| Copy of Newspaper Publication | 24-Jan-2025 |
Corporate Actions of Dr. Reddy's Laboratories Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share | 28-Oct-2024 |
| 1 | Annual General Meeting/Dividend - Rs 40 Per Share | 16-Jul-2024 |
| 1 | Annual General Meeting/Dividend - Rs 40 Per Share | 11-Jul-2023 |
| 1 | Annual General Meeting/Dividend - Rs 30 Per Share | 11-Jul-2022 |
| 1 | Annual General Meeting/Dividend - Rs 25 Per Share | 09-Jul-2021 |
| 1 | Annual General Meeting/Dividend - Rs 25 Per Share | 13-Jul-2020 |
| 1 | Annual General Meeting/Dividend - Rs 20 Per Share | 15-Jul-2019 |
| 1 | Annual General Meeting/Dividend- Rs 20 Per Share | 16-Jul-2018 |
| 1 | Annual General Meeting/Dividend - Rs 20/- Per Share | 17-Jul-2017 |
| 1 | Annual General Meeting/ Dividend - Rs 20/- Per Share | 18-Jul-2016 |
| 1 | Annual General Meeting/Dividend Rs 20/- Per Share | 10-Jul-2015 |
| 1 | Annual General Meeting / Final Dividend - Rs 18/- Per Share | 11-Jul-2014 |
| 1 | Annual General Meeting And Dividend Rs.15/- Per Share | 12-Jul-2013 |
| 1 | Annual General Meeting And Dividend - Rs.13.75 Per Share | 28-Jun-2012 |
| 1 | Annual General Meeting And Dividend Rs.11.25 Per Share | 30-Jun-2011 |
| 1 | Scheme Of Arrangement - Bonus Debentures 6:1 | 17-Mar-2011 |
| 1 | Annual General Meeting And Final Dividend Rs.11.25 Per Share | 02-Jul-2010 |
| 1 | Agm/Div-Rs.6.25 Per Share | 03-Jul-2009 |
| 1 | Agm/Dividend - 75% | 04-Jul-2008 |
| 1 | Dividend-75% | 06-Jul-2007 |
Board Meetings of Dr. Reddy's Laboratories Limited
Financial Results of Dr. Reddy's Laboratories Limited
| Qtr Ended | Tot. Income | Net P/L | EPS | Notes |
|---|---|---|---|---|
| 31 Dec 2024 | 525,040 | 84,940 | 10.2 | |
| 30 Sep 2024 | 690,390 | 188,210 | 22.6 | |
| 30 Jun 2024 | 605,900 | 141,720 | 85.1 | |
| 31 Mar 2024 | 531,750 | 103,480 | 62.14 | |
| 31 Dec 2023 | 433,060 | 47,520 | 28.55 |
Company Directory of Dr. Reddy's Laboratories Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.drreddys.com | Registered Office | 8-2-337,Road No.3, Banjara Hills, | HYDERABAD |
| www.drreddys.com | Transfer Agent | Bigshare Services Pvt. Ltd. 306, Right Wing, 3rd Floor,Amrutha Ville, Opp. Yashodha Hospital, Rajbhavan Road, Somajiguda, | HYDERABAD |
Insider Trading of Dr. Reddy's Laboratories Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Anjum Swaroop | 9252836 | Buy |
| 7(2) | C Swaminathan | 11307403 | Sell |
| 7(2) | Vincent Colicchio | 10445482 | Buy |
| 7(2) | Subba Inta | 4867456 | Buy |
| 7(2) | Juan Carlos Alvarez | 1002530 | Buy |
| 7(2) | Sanjay Choubey | 1486510 | Buy |
| 7(2) | Tricia Wetzel | 4040850 | Buy |
| 7(2) | C Swaminathan | 8643406 | Buy |
| 7(2) | Jeff Jorgenson | 3277236 | Buy |
| 7(2) | Bryan Dixon | 1037100 | Buy |
| 7(2) | Milan Kalawadia | 5627996 | Buy |
| 7(2) | EREZ ISRAELI | 445884700 | Buy |
| 7(2) | EREZ ISRAELI | 439598403 | Sell |
| 7(2) | Sonal Shah | 828934 | Buy |
| 7(2) | C Swaminathan | 3809438 | Buy |
| 7(2) | Tricia N Wetzel | 9763760 | Buy |
| 7(2) | Keerthi Kandlikar | 503936 | Buy |
| 7(2) | Jaya Lakshmi Ayyagari | 3168497 | Buy |
| 7(2) | John Roosenberg II | 1102220 | Buy |
| 7(2) | Uragasainareddy Medapati | 1007744 | Buy |
Annual Reports of Dr. Reddy's Laboratories Limited
Investor Complaints of Dr. Reddy's Laboratories Limited
| Date | Pending | Received | Disposed | Unresolved |
|---|---|---|---|---|
| 31-Dec-2024 | 0 | 3 | 3 | 0 |
| 31-Dec-2024 | 0 | 3 | 3 | 0 |
| 30-Sep-2024 | 0 | 0 | 0 | 0 |
| 30-Jun-2024 | 0 | 2 | 2 | 0 |
| 31-Mar-2024 | 0 | 1 | 1 | 0 |
| 31-Dec-2023 | 0 | 2 | 2 | 0 |
| 30-Sep-2023 | 0 | 5 | 5 | 0 |
| 30-Jun-2023 | 0 | 2 | 2 | 0 |
| 31-Mar-2023 | 0 | 3 | 3 | 0 |
| 31-Dec-2022 | 1 | 0 | 1 | 0 |
| 30-Sep-2022 | 0 | 5 | 4 | 1 |
| 30-Jun-2022 | 0 | 0 | 0 | 0 |
| 31-Mar-2022 | 0 | 1 | 1 | 0 |
| 31-Dec-2021 | 0 | 1 | 1 | 0 |
| 30-Sep-2021 | 0 | 1 | 1 | 0 |
| 30-Jun-2021 | 0 | 4 | 4 | 0 |
| 31-Mar-2021 | 0 | 3 | 3 | 0 |
| 31-Dec-2020 | 0 | 1 | 1 | 0 |
| 30-Sep-2020 | 0 | 3 | 3 | 0 |
| 30-Jun-2020 | 0 | 0 | 0 | 0 |
| 31-Mar-2020 | 0 | 1 | 1 | 0 |
| 31-Dec-2019 | 0 | 1 | 1 | 0 |
| 30-Sep-2019 | 0 | 1 | 1 | 0 |
| 30-Jun-2019 | 0 | 6 | 6 | 0 |
| 31-Mar-2019 | 0 | 2 | 2 | 0 |
| 31-Dec-2018 | 0 | 6 | 6 | 0 |
| 30-Sep-2018 | 0 | 1 | 1 | 0 |
| 30-Jun-2018 | 0 | 3 | 3 | 0 |
| 31-Mar-2018 | 0 | 4 | 4 | 0 |
| 31-Dec-2017 | 0 | 3 | 3 | 0 |
| 30-Sep-2017 | 0 | 3 | 3 | 0 |
| 30-Jun-2017 | 0 | 2 | 2 | 0 |
| 31-Mar-2017 | 0 | 3 | 3 | 0 |
| 31-Dec-2016 | 0 | 4 | 4 | 0 |
| 30-Sep-2016 | 0 | 3 | 3 | 0 |
| 31-Mar-2016 | 0 | 7 | 7 | 0 |
| 31-Dec-2015 | 0 | 3 | 3 | 0 |
Event Calendar of Dr. Reddy's Laboratories Limited
| Purpose | Details |
|---|---|
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2011 and recommend dividend, if any, for the financial year 2010-11. |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2012 and recommend dividend, if any, for the financial year 2011-12. |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2013 and recommend dividend, if any, for the financial year 2012-13. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30. 2013. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2013. |
| Results | to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2013. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2013. |
| Results | interalia,to consider the Audited Financial results for the financial year 2013-14 |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30. 2014. |
| Results | Inter-alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2014. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2014. |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2015 and recommend dividend, if any, for the financial year 2014-15. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2015. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2015. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2015. |
| Buyback | To consider the buyback of equity shares of the Company and other allied matters, as appropriate. |
| Results/Dividend | inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2016 and recommend dividend, if any, for the financial year 2015-16. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2016. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2016. |
| Results/Dividend | inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2017 and recommend dividend, if any, for the financial year 2016-17. Further, that the Company s trading window for dealing in securities by the Insiders is closed from April 26, 2017 and ending on May 14, 2017 (both days inclusive). |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the unaudited financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the unaudited financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Fund Raising | To consider fund raising through issuance of Commercial Papers |
| Financial Results/Dividend | DRREDDY : 20-May-2020 : The Company has informed the Exchange that a Board meeting to be held on May 13, 2020 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 20, 2020, To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the unaudited financial results for the quarter and half-year ended ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2021, and recommend dividend, if any, for the financial year 2020-21. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2021 and other business matters |
| Financial results | Dr. Reddy's Laboratories Limited has informed the Exchange about Board Meeting scheduled to be held on July 28, 2022, to consider and approve the Unaudited Financial Results of the Company for the quarter ending on June 30, 2022. |
| Financial results | Dr. Reddy's Laboratories Limited has informed the Exchange that a meeting of the Board of Directors of the Company will be held on Friday, October 28, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ending on September 30, 2022. |
| Financial Results | To inter-alia consider and approve the unaudited financial results for the quarter and nine months ending December 31, 2022 |
| Financial Results/Dividend | To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on March 31, 2023, and to recommend dividend, if any, for the financial year 2022-23. |
| Financial Results | To consider and approve the unaudited financial results for the quarter ending Jun 30, 2023 |
| Financial Results | To consider and approve the unaudited financial results for the quarter and half year ending September 30, 2023 |
| Financial Results | To consider and approve the unaudited financial results for the quarter and nine months ending December 31, 2023 |
| Financial Results/Dividend | To consider and approve the Audited Standalone and Consolidated financial results for quarter and financial year ending on March 31, 2024, and to recommend dividend, if any, for the financial year 2023-24 |
| Financial Results | To consider and approve the Unaudited financial results for the quarter ending June 30, 2024 |
| Stock Split | To consider stock split of equity shares |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Dr. Reddy's Laboratories Limited
Voting Results of Dr. Reddy's Laboratories Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 12-SEP-2024 | Postal Ballot | Approval of sub-division/split of each equity share of Rs. 5/- (Rupees five only) each into 5 (five) equity shares of Re. 1/- (Rupee one only) each and consequent alteration to the Memorandum of Association of the Company |
| 29-JUL-2024 | AGM | Adoption of the financial statements (standalone and consolidated) of the Company for the year ended March 31,2024, together with reports of the Board of Directors and Auditors thereon |
| 29-JUL-2024 | AGM | Remuneration payable to Cost Auditors, M/s.Sagar & Associates,Cost Accountants, for the financial year ending March 31,2025 |
| 29-JUL-2024 | AGM | Appointment of Mr. Vishal Reddy, a related party, as an entry level employee in Dr. Reddy￢ﾀﾙs Laboratories Inc, USA, a wholly owned subsidiary of the Company |
| 29-JUL-2024 | AGM | Re-Appointment of K Satish Reddy (DIN: 00129701), as a Director, who retires by rotation, and being eligible offers himself for re-appointment |
| 29-JUL-2024 | AGM | Declaration of Dividend of Rs.40 per share for the financial year ended March 31, 2024 |
| 14-FEB-2024 | Postal Ballot | Approval of the appointment of Mr. Sanjiv Soshil Mehta (DIN: 06699923) as an Independent Director of the Company, in terms of Section 149 of the Companies Act, 2013 |
| 15-NOV-2023 | Postal Ballot | Approval of appointment of Dr. Alpna Hansraj Seth (DIN: 01183914), as an Independent Director in terms of Section 149 of the Companies Act, 2013 |
| 27-JUL-2023 | AGM | Adoption of the financial statements(standalone and consolidated)of the Company for the year ended March 31,2023, together with reports of the Board of Directors and Auditors thereon |
| 27-JUL-2023 | AGM | Remuneration payable to Cost Auditors, M/s.Sagar & Associates,Cost Accountants, for the financial year ending March 31,2024 |
| 27-JUL-2023 | AGM | Re-Appointment of Ms.Shika Sharma (DIN:0043625) as an Independent Director for a second term of five years, in terms of Section 149 of the Companies Act,2013 |
| 27-JUL-2023 | AGM | Re-Appointment of Mr.Leo puri (DIN:01764813)as an Independent Director for a second term of five years, in terms of Section 149 of the Companies Act,2013 |
| 27-JUL-2023 | AGM | Appointment of Dr.Claudio Albrecht (DIN:10109819),as an Independent Director of the Company,in terms of Section 149 of the Companies Act,2013 |
| 27-JUL-2023 | AGM | Re-Appointment of Mr.G.V.Prasad (DIN:00057433),as a Director,who retires by rotation,and being eligible offers himself for re-appointment |
| 27-JUL-2023 | AGM | Declaration of Dividend of Rs.40 per share for the financial year ended March 31,2023 |
| 20-OCT-2022 | Postal Ballot | Approval of the appointment of Mr. Arun M Kumar (DIN: 09665138) as an Independent Director in terms of section 149 of the Companies Act,2013 |
| 29-JUL-2022 | AGM | Adoption of the Financial Statements (Standalone and Consolidated) of the Company for the year ended March 31, 2022, together with the reports of the Board of Directors and Auditors thereon. |
| 29-JUL-2022 | AGM | Approval of the reappointment of Mr. K Satish Reddy (DIN: 00129701) as a Whole-time Director, designated as Chairman |
| 29-JUL-2022 | AGM | Reappointment of Mr. K Satish Reddy (DIN: 00129701), as a director, who retires by rotation, and being eligible offers himself for the reappointment |
| 29-JUL-2022 | AGM | Declaration of dividend of Rs.30 per equity share for the financial year ended March 31, 2022. |